Guided by the motto, "Start with Integrity, Succeed through Action," Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry ...

It’s the hot-shot fix that took Hollywood — and now high school — by storm. Ozempic and other so-called “miracle” weight-loss ...

Novo Nordisk (NYSE: NVO) announced Thursday it will initiate Phase 3 trials for its experimental weight-loss drug amycretin in both injection and oral forms during the first quarter of 2026. The ...

Amycretin, the Danish drugmaker’s next-generation obesity drug, has a dual-mode action. Like its popular weight-loss drug ...

Novo Nordisk plans to initiate late-stage trials for its next-gen weight-loss drug, amycretin, by early 2026. The drug mimics ...

While these new drugs are curbing enthusiasm for eating, they are also having a notable effect on food purchases.

Tufts University scientists are aiming to revolutionize the future of weight loss drugs by engineering a new compound that ...

Regeneron signed a deal with China-based Hansoh Pharma for HS-20094, an investigational, late-stage anti-obesity asset. Per ...

Metsera is advancing promising obesity treatments with amylin and GLP-1 analogs, eyeing competitive efficacy and buyout ...

In what Guggenheim Partners called one of Metsera’s “critical program milestones” this year, its ultra-long-acting amylin ...

Global drugmakers, including generic drug manufacturers in India, are racing to develop their versions of blockbuster ...